SURVEILLE-HPV: Evaluation of HPV16 Circulating DNA as Biomarker to Detect the Recurrence, in Order to Improve Post Therapeutic Surveillance of HPV16-driven Oropharyngeal Cancers

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

RECRUITING

Clinical Phase

PHASE2

Total Enrollment

420 participants

Study Classification

INTERVENTIONAL

Study Start Date

2024-04-03

Study Completion Date

2031-04-01

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

SURVEILLE-HPV - A new post therapeutic surveillance strategy for HPV-driven oropharyngeal cancer based on HPV Circulating DNA measures.

HPV-positive oropharyngeal cancer patients have a much better prognosis that their HPV-negative counterparts. Despite this, Post Treatment Surveillance (PTS) strategy does not take into account HPV status.

HPV Circulating DNA (HPV Ct DNA) has emerged as a promising tool to assess the risk of cancer recurrence following treatment. We assume that this biomarker could be helpful to guide PTS.

The number of systematic PTS visits could be significantly reduced in patients with undetectable HPV Ct DNA whereas a closer clinical and radiological follow up could be performed in case of detectable HPV Ct DNA.

If confirmed, this new strategy could have several benefits including:

* reduction of PTS visits for most HPV-positive patients which implies a potential cost decrease and
* Identification of relapse at early stages (before the occurrence of symptoms)

Related Clinical Trials

Explore similar clinical trials based on study characteristics and research focus.

Post-treatment Surveillance in HPV+ Oropharyngeal SCC

NCT04965792

HPV Oropharyngeal Squamous Cell Carcinoma

ACTIVE_NOT_RECRUITING

Self-sampling and Human Papillomavirus (HPV)-Testing for Unscreened Women in Cervical Cancer Prevention

NCT01014026

Uterine Cervical Neoplasms Uterine Cervical Dysplasia

COMPLETED PHASE3

HPV Serum DNA Levels Predicting Outcome in p16+ Squamous Cell Head and Neck Cancer

NCT01984359

Subjects With p16 Positive/HPV Positive Squamous Cell Carcinomas of the Oropharynx

COMPLETED NA

SELF-CERV Pivotal Study: SELF-Collection for CERVical Cancer Screening

NCT06120205

Hpv HPV 16 Infection HPV Infection +1 more

ACTIVE_NOT_RECRUITING NA

Evaluation of HPV OncoTect ™ for the Etiological Diagnosis of HPV-induced Oropharyngeal Cancers

NCT03604588

Oropharyngeal Cancer

UNKNOWN NA

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Oropharynx Squamous Cell Carcinoma

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Allocation Method

RANDOMIZED

Intervention Model

PARALLEL

Primary Study Purpose

DIAGNOSTIC

Blinding Strategy

NONE

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

Standard follow-up monitoring (16 visits over 5 years)

Patients enrolled in the control arm will be monitored according to SFORL guidelines. Physical Examination (PE) will be carried out:

\- every 2 months the 1st year, every 3 months the 2nd year, every 4 months the 3rd year, every 6 months at 4 and 5 years.

Annual chest CT scan will be performed for current smokers \& for those who have quit smoking less than 15 years ago.

Group Type NO_INTERVENTION

No interventions assigned to this group

Lightened follow-up visits frequency (9 visits over 5 years), with HPV16 Ct-DNA dosing

Physical Examinations (with HPV16 Ct-DNA dosing) planned at Months 4,8,12,18,24,30,36,48,60 post treatment.

Annual chest CT scan will be performed for current smokers \& for those who have quit smoking less than 15 years ago.

Any patient with a normal PE but positive HPV16 ct-DNA test during follow-up period will require a confirmation test \~1-2 months later.

If HPV16 ct-DNA positivity is confirmed, an H\&N MRI /PET-CT will be performed. Then:

* If MRI and PET-CT are negative, the patient will be examined every 2 months (PE and HPV16 Ct-DNA dosing) and MRI/PET-CT will be repeated every 4-6 months, until HPV16 Ct-DNA becomes undetectable.
* If MRI and/or PET-CT is positive, the patient will get a biopsy to confirm disease recurrence. Once confirmed, the patient will have the necessary care, as per local practices, but will continue to be followed up within this study up to 5 years after treatment.

Group Type EXPERIMENTAL

HPV16 Ct-DNA dosing

Intervention Type BIOLOGICAL

Droplet based digital PCR (ddPCR) technology is a novel method for performing digital PCR. A sample is fractionated into 20,000 droplets, PCR amplification of the template molecules occurs in each individual droplet.

ddPCR allows to generate quantitative and accurate data without standard curves and also present higher sensitivity compared to conventional quantitative PCR (qPCR). Indeed, this method is based on the realization of millions of single-molecule PCRs in parallel in independent compartment (here droplets of an emulsion) and consequently avoids the bias seen in conventional PCR.

ddPCR offers an optimized approach for the sensitive detection and quantification of low-target-abundance biological samples.

DNA extraction will be planned on 1 mL of plasma, which will further increase the sensitivity of our technique initially based on only 200µL of DNA extracted plasma.

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

HPV16 Ct-DNA dosing

Droplet based digital PCR (ddPCR) technology is a novel method for performing digital PCR. A sample is fractionated into 20,000 droplets, PCR amplification of the template molecules occurs in each individual droplet.

ddPCR allows to generate quantitative and accurate data without standard curves and also present higher sensitivity compared to conventional quantitative PCR (qPCR). Indeed, this method is based on the realization of millions of single-molecule PCRs in parallel in independent compartment (here droplets of an emulsion) and consequently avoids the bias seen in conventional PCR.

ddPCR offers an optimized approach for the sensitive detection and quantification of low-target-abundance biological samples.

DNA extraction will be planned on 1 mL of plasma, which will further increase the sensitivity of our technique initially based on only 200µL of DNA extracted plasma.

Intervention Type BIOLOGICAL

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

1. Patient aged 18 years or over
2. Patient with p16 positive Oropharyngeal squamous cell carcinoma (OPSCC)
3. Clinical stage T1-4, N0-3, M0 (stages I-III)
4. Any tobacco status
5. Life expectancy greater than 36 months
6. Positive HPV16 Ct-DNA measured before curative anticancer treatment
7. Treated by any curative treatment
8. Complete response at 3 months after end of treatment, which means:

* Undetectable HPV16 Ct-DNA and no residual disease on imaging (group A) or
* Undetectable HPV16 Ct-DNA and suspicious imaging but persistent disease excluded by either biopsy or repeated imaging (group B1) or
* Positive HPV16 Ct-DNA and no residual disease on imaging but negative HPV16 Ct-DNA on the subsequent assessment. This second test will be done 1-2 months after the first one (group C1).
9. Patient must be affiliated to a Social Security System (or equivalent)
10. Patients must have signed a written informed consent form prior to any trial specific procedures. If the patient is physically unable to give his/her written consent, a trusted person of his/her choice, note related to the investigator or the sponsor, can confirm in writing the patient's consent.

Exclusion Criteria

1. Uncontrolled intercurrent illness that would limit compliance with study requirements.
2. Active invasive malignancy within 3 years of inclusion except for non-invasive malignancies such as non-melanomatous carcinoma of the skin or ductal carcinoma in situ of the breast that has/have been surgically cured.
3. Any other HPV induced cancer within 5 years
4. Any condition that may jeopardize the patient participation as well as non-contraception for male and female with child-bearing potential, pregnancy or breast-feeding
5. Patient unwilling or unable to comply with the study protocol and follow-up schedule.
6. Participation in another clinical trial with an investigational medical product during the last 30 days prior to the inclusion and during the present study (except if patient is included in the control arm, with placebo or with a product that have a marketed authorization, used as per the summary of product characteristics (SmPC) for the given indication).
7. Patient deprived of liberty or placed under protective custody or guardianship.

Minimum Eligible Age

18 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

No